×

How we’re leading UK pharmacovigilance

Here at the Drug Safety Research Unit, we are proud to be the UK's leading pharmacovigilance and pharmacoepidemiology unit.  We have conducted hundreds of post-authorisation...

Continue reading

International group redoubles efforts to improve detection of drug side effects

The International Working Group (IWG) on New Developments in Pharmacovigilance has resumed its work in earnest, following an extended break due to the pandemic. Members...

Continue reading

30 September 2022

Just published: our paper on cases of thrombosis with concurrent thrombocytopenia following AstraZeneca Covid-19 vaccine.

In March 2021, rare signals of unusual clotting with concurrent low platelets began to emerge in people who had received at least one dose of...

Continue reading

Good to be back at ICPE!

The DSRU had a great conference at ICPE (International Conference on Pharmacoepidemiology & Therapeutic Risk Management) in Copenhagen last week. The in-person annual conference of...

Continue reading

20 May 2022

Our biennial Signal Detection conference is back!

After an extended break due to the pandemic, we are delighted that our iconic 11th Biennial Conference on Signal Detection and Signal Management in Pharmacovigilance...

Continue reading

18 May 2022

Risk minimisation at the DSRU

“The right medicine, at the right dose, at the right time, to the right patient” (GVP, Module XVI) Risk minimisation measures are actions taken to...

Continue reading

9 May 2022

DSRU hosts ISoP Mid-Year Symposium

Beyond Spontaneous Reporting: integrating data from multiple sources to ensure medicines safety The Drug Safety Research Unit (DSRU) hosts an important international meeting for the...

Continue reading

22 March 2022

Institute of Pharmacovigilance Sciences launched to improve global drug safety research methods

The  Drug Safety Research Unit has today launched a new global Institute of Pharmacovigilance Sciences. A team of DSRU physicians, epidemiologists and biomedical scientists will...

Continue reading

17 March 2022

DSRU launches Institute of Pharmacovigilance Sciences with free webinar

The DSRU Institute of Pharmacovigilance Sciences has been established to build on the DSRU’s  methodological research in pharmacovigilance and pharmacoepidemiology. The launch of the Institute...

Continue reading

8 March 2022

DSRU expands research team and 80% are women, nearly double the UK average in science roles

Ahead of International Women’s Day on Tuesday 8 March, the UK’s independent Drug Safety Research Unit (DSRU) has announced it’s doubled the size of its...

Continue reading

3 March 2022

Myocarditis and pericarditis in immunocompromised patients following COVID-19 mRNA vaccination

Summary: Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination Two years after the start...

Continue reading

3 December 2021

The DSRU and the Future of UK Pharmacoepidemiology & Pharmacovigilance

The DSRU has expanded enormously in the last few years.  As the UK’s premier unit for pharmacoepidemiology and pharmacovigilance, we have a full understanding of the...

Continue reading

17 September 2021

Pericarditis and myocarditis following mRNA vaccination: our review

The UK’s independent Drug Safety Research Unit (DSRU) has concluded that heart inflammation after mRNA COVID-19 vaccines is very rare and mild in the vast...

Continue reading

25 August 2021

Podcast: how we have been monitoring the safety of Covid vaccines

Listen to Saad Shakir on the MedTalk Podcast: Understanding Covid-19 vaccines with the DSRU. The DSRU is monitoring the safety of most of the UK’s...

Continue reading

2 August 2021

Vaccination provides weaker COVID-19 protection for immunocompromised patients

The DSRU Global Pharmacovigilance Observatory recently completed a systematic review of multiple studies comparing the immune response to COVID-19 vaccines in immunocompromised patients with that...

Continue reading

16 July 2021

DSRU Observational Studies on the COVID19 vaccines

Recruitment of participants is almost complete for our post-authorisation study to monitor the safety of the AstraZeneca COVID-19 vaccine. The study uses active surveillance methodology,...

Continue reading

6 April 2021

Pharmacovigilance Evidence Review: Rare blood clots with AstraZeneca COVID-19 vaccine in women under 55

Rare blood clots with AstraZeneca COVID-19 vaccine in women under 55 The DSRU has evaluated all publicly available data on blood clotting incidents after immunisation...

Continue reading

12 March 2021

Pharmacovigilance Evidence Review: Thrombosis following vaccination with COVID-19 AstraZeneca Vaccine

Professor Saad Shakir and Samantha Lane 12 March 2021 We agree with MHRA and EMA that people should continue to be vaccinated with the Oxford/AstraZeneca...

Continue reading

23 November 2020

Investigating Serious Adverse Events in COVID-19 Vaccine Trials

Despite the urgent need for a COVID-19 vaccine, it is of critical importance that the process of safety evaluation is not compromised in any way....

Continue reading

13 November 2020

Drugs repurposed for COVID-19 still need rigorous testing

Existing drugs repurposed to treat COVID-19 still need rigorous testing for safety and effectiveness and the DSRU is urging institutions across the globe to work...

Continue reading

6 November 2020

Rivaroxaban hospital PASS (ROSE study) papers published!

Two papers on the findings of our Rivaroxaban Observational Safety Evaluation (ROSE) study have just been published. ROSE is is a prime example of our...

Continue reading

22 October 2020

Paper published: Can post-marketing studies provide a safety net for COVID-19 vaccines in the UK?

Our new paper published in BMJ Evidence Based Medicine explains that, given the speed with which potential new COVID-19 vaccines are being developed, it is...

Continue reading

14 October 2020

DSRU comment on pausing of J&J COVID-19 vaccine trial

Director, Professor Saad Shakir,  said: “Serious adverse events are expected in a clinical trial that includes 60,000 vaccinees. While the independent Data Safety Monitoring Board...

Continue reading

5 October 2020

Remdesivir for COVID-19 patients is ‘favourable’ says first systematic benefit-risk study

Remdesivir for COVID-19 patients is ‘favourable’ says first systematic benefit-risk study The first comprehensive evaluation of all possible benefits and risks of remdesivir The benefits...

Continue reading

18 September 2020

DSRU presents first ISoP journal club!

DSRU Senior Clinical Research Fellow, Dr Miranda Davies, and Director, Professor Saad Shakir, presented the first ever online journal club for the International Society of...

Continue reading

27 August 2020

Insufficient evidence for use of convalescent plasma in COVID-19 patients

Convalescent plasma (CP) treatment is one treatment option currently being investigated in COVID-19. Our review of evidence for a living systematic benefit-risk assessment of the...

Continue reading

11 August 2020

The One Million Study to monitor safety and effectiveness of COVID-19 vaccines

Our UK COVID-19 Vaccine Consortium has announced plans for the One Million Post-Authorisation Study to monitor the safety and effectiveness of the COVID-19 vaccine in...

Continue reading

29 June 2020

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment

Our dynamic systematic benefit-risk analysis of antiviral drug combination lopinavir-ritonavir for COVID-19 patients has just been published. Our research team found there was no clear...

Continue reading

22 June 2020

New consortium to monitor safety and effectiveness of COVID-19 vaccines

A new consortium to monitor the safety and effectiveness of COVID-19 vaccines has been formed by the Drug Safety Research Unit and MEMO Research, University...

Continue reading

29 May 2020

First systematic benefit-risk assessment of Remdesivir published

Remdesivir for COVID-19 patients is ‘favourable’ says first systematic benefit-risk study We have just published the first ever systematic benefit-risk analysis of antiviral drug remdesivir...

Continue reading

27 May 2020

Hospital PASS studies: conducting real-world observational studies in secondary care

Our article in the Spring edition of Pharmafile explains our unique SCEM method for conducting PASS studies in hospitals and specialist care in the context...

Continue reading

14 May 2020

The need for active surveillance of the safety and effectiveness of COVID-19 vaccines

(First published as a BMJ Rapid Response on 12th May 2020) A key component of efforts to control COVID-19 will be an effective vaccine. There...

Continue reading

30 April 2020

COVID-19: DSRU’s latest research and capabilities update

The DSRU team is heavily engaged in conducting studies related to the COVID-19 pandemic. Dozens of clinical trials are underway around the world, many on...

Continue reading

28 April 2020

Business as usual at the DSRU

The DSRU team is used to working remotely while maintaining high standards and completing studies on time. We have the connectivity to enable us to...

Continue reading

30 March 2020

Article: The need for evolution in pharmacovigilance

Pharmafocus published an interview with our Director, Saad Shakir, in its March issue, focusing on the need for pharmacovigilance to evolve in order to handle...

Continue reading

26 February 2020

Systematic Benefit-Risk Assessment published

Benefit-risk assessment is used to weigh up the benefits of a specific treatment with the risks of that treatment. The DSRU team has just published...

Continue reading

26 February 2020

Developing Gravitas: A masterclass in maximising your leadership potential

Improving your presence and impact in your organisation We are delighted to be working in collaboration with The Gravitas Programme to bring you a new...

Continue reading

7 February 2020

Milestone 20 years for DSRU pharmacovigilance training

DSRU Education & Training is celebrating two decades of training health and pharmaceutical professionals, many of whom have gone on to senior UK pharmacovigilance roles....

Continue reading

20 January 2020

New course for 2020 – Vigilance of Medical Devices

Addressing the uncertainty around implementation of the Medical Devices Regulation (MDR) The new European regulations on medical devices entered into force in 2017 and must...

Continue reading

3 January 2020

Improvements needed in recording brand and batch numbers for biological medicines to ensure patient safety

Health professionals need to improve how they record brand and batch numbers for biologic medicines to ensure patients stay safe, according to a new study...

Continue reading

5 November 2019

GPs urged to help improve patient safety

The DSRU had coverage in the BMJ last week following the issue of the press release below. The article is available to BMJ subscribers here....

Continue reading

25 October 2019

DSRU team at RCGP Annual Conference!

The DSRU team is delighted to be at the Annual Conference of the Royal College of General Practitioners (RCGP) in Liverpool. Our medics are on...

Continue reading

14 October 2019

Improving detection of adverse drug reactions

DSRU Director, Professor Saad Shakir, attended a three day meeting in Erice in Sicily on “Improving the Detection Analysis and Reporting Harms in Medicines”. The...

Continue reading

8 October 2019

Expanding the reach of Pharmacovigilance education with the Royal Pharmaceutical Society

The DSRU is delighted to be collaborating with the Royal Pharmaceutical Society to deliver two new training days. The courses are designed to introduce the...

Continue reading

24 September 2019

DSRU Consultancy: World class science at a not for profit price!

DSRU Consultancy has a small flexible team of epidemiologists, clinicians and pharmacists. Watch this short video to find out how DSRU Consultancy provides advice in pharmacoepidemiology, pharmacovigilance, risk minimisation and...

Continue reading

13 September 2019

Success of Big Data for Pharmacovigilance Conference!

The DSRU’s Second Conference on Big Data for Pharmacovigilance has been a great success. Delegates from regulatory bodies, the pharmaceutical industry and academia have heard...

Continue reading

27 August 2019

The DSRU is at ICPE in Philadelphia!

The DSRU team is attending the International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) in Philadelphia. Come and meet our team at booth 204,...

Continue reading

2 August 2019

Big Data for Pharmacovigilance: looking forward to our 2nd conference!

Our second conference on Big Data for Pharmacovigilance takes place in September in London. We have an impressive line-up of speakers who will examine the...

Continue reading

26 July 2019

The importance of recording brand and batch numbers of prescribed biologic medicines

In 2017-18, the NHS saved over £200 million by using more biosimilar medicines1. In 2018, NHS England announced plans to increase the uptake of biosimilars...

Continue reading

23 July 2019

Congratulations to our 2019 Graduates!

Congratulations to our students who graduated from Masters in Pharmacovigilance earlier this month. Students graduating either completed their Postgraduate Certificate, Diploma or Masters in Pharmacovigilance,...

Continue reading

8 July 2019

IWG on Signal Detection & Management holds launch call

The launch teleconference for the International Working Group (IWG) on Signal Detection and Management in Pharmacovigilance took place last week. The key points raised included:...

Continue reading

28 June 2019

IWG on Signal Detection & Management gets underway!

The International Working Group (IWG) on Signal Detection and Management in Pharmacovigilance is taking shape.  The IWG now includes members from nearly 20 pharmaceutical companies,...

Continue reading

11 June 2019

10th Conference on Signal Detection & Management is underway!

10th Conference on Signal Detection & Management is underway! Our 10th Biennial Conference on Signal Detection and Management is now underway. Today we have a...

Continue reading

14 March 2019

Mental Health Awareness Week: Spotlight on ECHO

In this week’s PharmaTimes article, Professor Allan Young (Institute of Psychiatry, King’s College London) explains why the unique service offered by ECHO  (European Consortium for...

Continue reading

8 May 2019

How does DSRU Consultancy work?

The DSRU Consultancy has a small flexible team of epidemiologists, clinicians and pharmacists. Watch this short video to find out how DSRU Consultancy provides advice...

Continue reading

29 April 2019

DSRU: Experts at Post-authorisation Safety Studies (PASS)

Here at the DSRU, we are experts at conducting Post-authorisation Safety Studies (PASS) on medicines prescribed in primary, secondary and specialist care. If your company...

Continue reading

5 April 2019

Meet the DSRU team at ISPE Mid Year in Rome!

A small team from the DSRU will be at the International Society for Pharmacoepidemiology (ISPE) Mid Year conference in Rome. Come and find us in...

Continue reading

26 March 2019

What our research on UK drug withdrawals can tell the Independent Medicines and Medical Devices Safety Review

By Dr Elizabeth Lynn, Head of Scientific Development and Education at the Drug Safety Research Unit. Monitoring adverse side effects is our core focus at...

Continue reading

26 March 2019

Launch of the International Working Group on Signal Detection and Management in Pharmacovigilance

This week we launch the International Working Group (IWG) on Signal Detection and Management in Pharmacovigilance. Experts from over 20 organisations in the pharma industry...

Continue reading

11 March 2019

DSRU: Experts in hospital PASS Studies

The DSRU is highly unusual in its capability to conduct PASS studies in hospitals or specialist care. These studies follow our Specialist Cohort Event Monitoring (SCEM)...

Continue reading

28 February 2019

European Network Studies

Conducting post-authorisation studies in more than one country has several advantages: Local investigators will have a good understanding of the healthcare system in their country....

Continue reading